



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
02.03.2022 Bulletin 2022/09

(45) Date of publication and mention
of the grant of the patent:
26.01.2022 Bulletin 2022/04

(21) Application number: **19174121.4**

(22) Date of filing: **16.07.2015**

(51) International Patent Classification (IPC):
A61K 35/768 ^(2015.01) **C07K 16/18** ^(2006.01)
A61K 35/765 ^(2015.01) **A61K 9/00** ^(2006.01)
A61K 47/02 ^(2006.01) **A61K 9/08** ^(2006.01)
A61K 35/761 ^(2015.01) **A61K 35/763** ^(2015.01)
A61K 35/766 ^(2015.01) **C07K 14/535** ^(2006.01)
C07K 16/28 ^(2006.01) **C12N 9/10** ^(2006.01)
C12N 9/80 ^(2006.01) **A61K 45/06** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61K 35/768; A61K 9/0019; A61K 9/08;
A61K 35/761; A61K 35/763; A61K 35/765;
A61K 35/766; A61K 47/02; A61P 1/00; A61P 1/16;
A61P 11/00; A61P 13/08; A61P 13/12;
A61P 35/00; C07K 14/535; (Cont.)

(54) **ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS**

ONKOLYTISCHES VIRUS ZUR EXPRESSION VON IMMUNOLOGISCHEN
PRÜFPUNKTMODULATOREN

VIRUS ONCOLYTIQUE POUR L'EXPRESSION DE MODULATEURS DE POINT DE CONTRÔLE
IMMUNITAIRE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **16.07.2014 EP 14306153**

(43) Date of publication of application:
16.10.2019 Bulletin 2019/42

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
15738359.7 / 3 169 341

(73) Proprietor: **TRANSGENE**
67400 Illkirch Graffenstaden (FR)

(72) Inventors:
• **SILVESTRE, Nathalie**
67120 ERGERSHEIM (FR)
• **GEIST, Michel**
67170 BRUMATH (FR)
• **RITTNER, Karola**
67100 STRASBOURG (FR)

• **MARCHAND, Jean-Baptiste**
67210 OBERNAI (FR)
• **THIOUDELLET, Christine**
67000 STRASBOURG (FR)

(74) Representative: **Regimbeau**
20, rue de Chazelles
75847 Paris Cedex 17 (FR)

(56) References cited:
WO-A1-2009/065546 WO-A1-2014/047350
WO-A1-2019/178101 WO-A1-2020/049001
CN-A- 108 165 536 CN-A- 110 218 707

• **J D DIAS ET AL: "Targeted cancer**
immunotherapy with oncolytic adenovirus
coding for a fully human monoclonal antibody
specific for CTLA-4", GENE THERAPY, 10
November 2011 (2011-11-10), XP055015331,
ISSN: 0969-7128, DOI: 10.1038/gt.2011.176

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- J. D. DIAS ET AL: "Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1", CLINICAL CANCER RESEARCH, vol. 16, no. 9, 13 April 2010 (2010-04-13) , pages 2540-2549, XP055214478, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-2974
- T DU ET AL: "Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers", CANCER GENE THERAPY, vol. 21, no. 8, 18 July 2014 (2014-07-18), pages 340-348, XP055214039, ISSN: 0929-1903, DOI: 10.1038/cgt.2014.34
- CHRISTINE E ENGELAND ET AL: "CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy", MOLECULAR THERAPY, vol. 22, no. 11, 26 August 2014 (2014-08-26), pages 1949-1959, XP055158410, ISSN: 1525-0016, DOI: 10.1038/mt.2014.160
- MAXINE BAUZON ET AL: "Armed Therapeutic Viruses - A Disruptive Therapy on the Horizon of Cancer Immunotherapy", FRONTIERS IN IMMUNOLOGY, vol. 5, 1 February 2014 (2014-02-01), XP055214432, DOI: 10.3389/fimmu.2014.00074
- DON B GAMMON ET AL: "Vaccinia Virus-Encoded Ribonucleotide Reductase Subunits Are Differentially Required for Replication and Pathogenesis", P L O S PATHOGENS (PRINT), PUBLIC LIBRARY OF SCIENCE, US, vol. 6, no. 7, 8 July 2010 (2010-07-08), pages e1000984-1, XP008150295, ISSN: 1553-7366, DOI: 10.1371/JOURNAL.PPAT.1000984
- KYLE G. POTTS ET AL: "Oncolytic Viruses in the Treatment of Bladder Cancer", ADVANCES IN UROLOGY, vol. 2012, 1 January 2012 (2012-01-01), pages 1-11, XP055443442, ISSN: 1687-6369, DOI: 10.1155/2012/404581
- WOO YANGHEE ET AL: "Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer", JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, COLLEGE, CHICAGO, IL, US, vol. 230, no. 4, 4 February 2020 (2020-02-04), pages 709-717, XP086103159, ISSN: 1072-7515, DOI: 10.1016/J.JAMCOLLSURG.2019.12.027 [retrieved on 2020-02-04]

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

- (52) Cooperative Patent Classification (CPC): (Cont.)
C07K 16/2818; C12N 9/1077; C12N 9/80;
C12Y 204/02009; C12Y 305/01023;
 A61K 2039/505; C07K 2317/55; C07K 2317/622;
 C07K 2317/76; C12N 2710/24121;
 C12N 2710/24132